KLI

Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis

Metadata Downloads
Abstract
Purpose Data from common clinical practice were used to generate balanced cohorts of patients receiving either sorafenib or lenvatinib, for unresectable hepatocellular carcinoma, with the final aim to investigate their declared equivalence.

Methods Clinical features of lenvatinib and sorafenib patients were balanced through inverse probability of treatment weighting (IPTW) methodology, which weights patients' characteristics and measured outcomes of each patient in both treatment arms. Overall survival was the primary endpoint and occurrence of adverse events was the secondary.

Results The analysis included 385 patients who received lenvatinib, and 555 patients who received sorafenib. In the unadjusted cohort, lenvatinib did not show a survival advantage over sorafenib (HR: 0.85, 95% CI 0.70-1.02). After IPTW adjustment, lenvatinib still not returned a survival advantage over sorafenib (HR: 0.82, 95% CI: 0.62-1.07) even in presence of balanced baseline characteristics. Lenvatinib provided longer survival than sorafenib in patients previously submitted to TACE (HR: 0.69), with PS of 0 (HR: 0.73) or without extrahepatic disease (HR: 0.69).

Conclusion Present results confirmed randomized controlled trial in the real-life setting, but also suggests that in earlier stages some benefit can be expected.
Author(s)
김형돈방영학유창훈Alessandro CucchettiAndrea Casadei-GardiniAtsushi HiraokaCaterina SoldaCaterina VivaldiEi ItobayashiFabio PiscagliaGianluca MasiHidenori ToyodaHironori KogaKunihiko TsujLorenza RimassaLuca Giovanni FrassinetiMargherita RiminiMario ScartozziMasanori AtsukawaSara L
Issued Date
2021
Type
Article
Keyword
extrahepatic diseaselenvatinibperformance statussorafenibsurvivaltrans-arterial chemoembolization.
DOI
10.1111/liv.14817
URI
https://oak.ulsan.ac.kr/handle/2021.oak/8445
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_proquest_miscellaneous_2487155261&context=PC&vid=ULSAN&lang=ko_KR&search_scope=default_scope&adaptor=primo_central_multiple_fe&tab=default_tab&query=any,contains,Lenvatinib%20versus%20sorafenib%20in%20first-line%20treatment%20of%20unresectable%20hepatocellular%20carcinoma:%20An%20inverse%20probability%20of%20treatment%20weighting%20analysis&offset=0&pcAvailability=true
Publisher
LIVER INTERNATIONAL
Location
미국
Language
한국어
ISSN
1478-3223
Citation Volume
41
Citation Number
6
Citation Start Page
1389
Citation End Page
1397
Appears in Collections:
Medicine > Medicine
Authorize & License
  • Authorize공개
Files in This Item:
  • There are no files associated with this item.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.